SLOAN-KETTERING INST CAN RESEARCH
Prolidase Inhibitors as Therapeutic Agents for Acute Myeloid Leukemia
Prolidase Inhibitors as Therapeutic Agents for Acute Myeloid Leukemia is a funding opportunity from SLOAN-KETTERING INST CAN RESEARCH, up to 609576, closing February 28, 2027.
Feb 28, 2027
(212d left)Overview
PROJECT SUMMARY Acute myeloid leukemia (AML) is the most common form of leukemia in adults. New therapeutic strategies are urgently needed for AML, as the overall five-year survival rate remains at less than 25 percent. Agents that activate the CARD8 inflammasome were recently discovered to trigger a non-inflammatory…